Literature DB >> 23886812

Cyclopropane-based conformational restriction of GABA by a stereochemical diversity-oriented strategy: identification of an efficient lead for potent inhibitors of GABA transports.

Kazuaki Nakada1, Mamie Yoshikawa, Soichiro Ide, Akihiro Suemasa, Shuhei Kawamura, Takaaki Kobayashi, Eiji Masuda, Yoshihiko Ito, Wataru Hayakawa, Takahiro Katayama, Shizuo Yamada, Mitsuhiro Arisawa, Masabumi Minami, Satoshi Shuto.   

Abstract

A series of cyclopropane-based conformationally restricted γ-aminobutyric acid (GABA) analogs with stereochemical diversity, that is, the trans- and cis-2,3-methano analogs Ia and Ib and their enantiomers ent-Ia and ent-Ib, and also the trans- and cis-3,4-methano analogs IIa and IIb and their enantiomers ent-IIa and ent-Iib, were synthesized from the chiral cyclopropane units Type-a and Type-b that we developed. These analogs were systematically evaluated with four GABA transporter (GAT) subtypes. The trans-3,4-methano analog IIa had inhibitory effects on GAT3 (IC50=23.9μM) and betaine-GABA transporter1 (5.48μM), indicating its potential as an effective lead compound for the development of potent GAT inhibitors due to its hydrophilic and low molecular weight properties and excellent ligand efficiency.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  1-(2-[tris(4-methoxyphenyl)methoxy]ethyl)-3-piperidinecarboxylic acid; ANOVA; BGT; BGT1; CHO; CNS; Chinese hamster ovary; Conformational restriction; Cyclopropane; EPM; GABA; GABA transporter; GAT; GAT3; LE; PTZ; SNAP; SSRI; analysis of variance; betaine-GABA transporter; central nervous systems; elevated plus maze; ligand efficiency; pentylenetetrazole; serotonin-selective reuptake inhibitors; γ-aminobutyric acid

Mesh:

Substances:

Year:  2013        PMID: 23886812     DOI: 10.1016/j.bmc.2013.06.063

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Conformationally Restricted GABA with Bicyclo[3.1.0]hexane Backbone as the First Highly Selective BGT-1 Inhibitor.

Authors:  Takaaki Kobayashi; Akihiro Suemasa; Arisa Igawa; Soichiro Ide; Hayato Fukuda; Hiroshi Abe; Mitsuhiro Arisawa; Masabumi Minami; Satoshi Shuto
Journal:  ACS Med Chem Lett       Date:  2014-06-16       Impact factor: 4.345

2.  GRID-independent molecular descriptor analysis and molecular docking studies to mimic the binding hypothesis of γ-aminobutyric acid transporter 1 (GAT1) inhibitors.

Authors:  Sadia Zafar; Ishrat Jabeen
Journal:  PeerJ       Date:  2019-01-31       Impact factor: 2.984

Review 3.  Rational approaches for the design of various GABA modulators and their clinical progression.

Authors:  Kavita Bhagat; Jatinder V Singh; Piyusha P Pagare; Nitish Kumar; Anchal Sharma; Gurinder Kaur; Nihar Kinarivala; Srinivasa Gandu; Harbinder Singh; Sahil Sharma; Preet Mohinder S Bedi
Journal:  Mol Divers       Date:  2020-03-13       Impact factor: 2.943

Review 4.  Structure, Function, and Modulation of γ-Aminobutyric Acid Transporter 1 (GAT1) in Neurological Disorders: A Pharmacoinformatic Prospective.

Authors:  Sadia Zafar; Ishrat Jabeen
Journal:  Front Chem       Date:  2018-09-11       Impact factor: 5.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.